Evidence map›Paper›PMID 26869584›Full record

ArticleThe oncologist2016

Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT.

Sebastian Giebel, Myriam Labopin, Adalberto Ibatici, Paul Browne, Tomasz Czerw, Gerard Socie, Ali Unal, Slawomira Kyrcz-Krzemien, Andrea Bacigalupo, Hakan Goker and 9 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in The oncologist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Increasing access to allogeneic hematopoietic cell transplant: an international perspective.Hematology. American Society of Hematology. Education Program · 2021
    Article
  3. Article
  4. Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 16 institutions in 9 countries.

Sebastian GiebelMaria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Gliwice, Poland sgiebel@io.gliwice.pl.
Myriam LabopinHospital Saint-Antoine, Asistance Publique Hopitaux de Paris, Paris, France European Group for Blood and Marrow Transplantation, Acute Leukemia Working Party Office, Hospital Saint Antoine, Paris, France Universite Pierre et Marie Curie, Paris, France INSERM Unités Mixtes de Recherche 938, Paris, France.
Adalberto IbaticiAzienda Ospedaliera Universitaria San Martino Istituto di Ricovero e Cura a Carattere Scientifico, Genova, Italy.
Paul BrowneSt. James's Hospital, Dublin, Ireland.
Tomasz CzerwMaria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Gerard SocieHopital St. Louis, Paris, France.
Ali UnalErciyes Medical School, Kapadokya Bone Marrow Transplanatation Center, Kayseri, Turkey.
Slawomira Kyrcz-KrzemienSilesian Medical University, Katowice, Poland.
Andrea BacigalupoAzienda Ospedaliera Universitaria San Martino Istituto di Ricovero e Cura a Carattere Scientifico, Genova, Italy.
Hakan GokerHacettepe University, Ankara, Turkey.
Mike PotterTrustee of London Clinic, London, United Kingdom.
Caroline L FurnessTrustee of London Clinic, London, United Kingdom.
Grant McQuakerBeatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Dietrich BeelenUniversity Hospital, Essen, Germany.
Noel MilpiedUniversity Hospital and University of Bordeaux, Pessac, France.
Antonio CamposInstituto Portuguęs de Oncologia do Porto, Porto, Portugal.
Charles CraddockQueen Elizabeth Hospital, Birmingham, United Kingdom.
Arnon NaglerEuropean Group for Blood and Marrow Transplantation, Acute Leukemia Working Party Office, Hospital Saint Antoine, Paris, France Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Mohamad MohtyHospital Saint-Antoine, Asistance Publique Hopitaux de Paris, Paris, France European Group for Blood and Marrow Transplantation, Acute Leukemia Working Party Office, Hospital Saint Antoine, Paris, France Universite Pierre et Marie Curie, Paris, France INSERM Unités Mixtes de Recherche 938, Paris, France.
London Clinic · GBOspedale Policlinico San Martino · ITThe Maria Sklodowska-Curie National Research Institute of Oncology · PLBeatson West of Scotland Cancer Centre · GBErciyes University · TREssen University Hospital · DEEuropean Society for Blood and Marrow Transplantation · FRHacettepe University · TRHôpital Saint-Antoine · FRHôpital Saint-Louis · FRIPO Porto · PTMedical University of Silesia · PLQueen Elizabeth Hospital Birmingham · GBSorbonne Université · FRSt. James's Hospital · IEUniversité de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFrom a global perspective, the rates of allogeneic hematopoietic cell transplantation (alloHCT) are closely related to the economic status of a country. However, a potential association with outcome has not yet been documented. The goal of this study was to evaluate effects of health care expenditure (HCE), Human Development Index (HDI), team density, and center experience on nonrelapse mortality (NRM) after HLA-matched sibling alloHCT for adults with acute lymphoblastic leukemia (ALL). PATIENTS AND

methodsA total of 983 patients treated with myeloablative alloHCT between 2004 and 2008 in 24 European countries were included.

resultsIn a univariate analysis, the probability of day 100 NRM was increased for countries with lower current HCE (8% vs. 3%; p = .06), countries with lower HDI (8% vs. 3%; p = .02), and centers with less experience (8% vs. 5%; p = .04). In addition, the overall NRM was increased for countries with lower current HCE (21% vs. 17%; p = .09) and HDI (21% vs. 16%; p = .03) and for centers with lower activity (21% vs. 16%; p = .07). In a multivariate analysis, the strongest predictive model for day 100 NRM included current HCE greater than the median (hazard ratio [HR], 0.39; p = .002). The overall NRM was mostly predicted by HDI greater than the median (HR, 0.65; p = .01). Both lower current HCE and HDI were associated with decreased probability of overall survival.

conclusionBoth macroeconomic factors and the socioeconomic status of a country strongly influence NRM after alloHCT for adults with ALL. Our findings should be considered when clinical studies in the field of alloHCT are interpreted.

Indexed as

Health Care CostsSocioeconomic FactorsAdolescentAdultFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesTransplantation, HomologousTreatment OutcomeYoung AdultAcute lymphoblastic leukemiaHealth care expenditureHematopoietic cell transplantationHuman development indexNon-relapse mortality

Identifiers

PMID26869584
PMCPMC4786353
OpenAlexW2258870492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.